Nesvacumab

Drug Overview

Nesvacumab (also known as REGN910) is an investigational, fully human monoclonal antibody designed to target and bind to Angiopoietin-2 (Ang-2). It is a member of the anti-angiogenic class of drugs, which work by disrupting the blood supply that tumors need to grow and spread. Unlike common anti-angiogenic agents that target VEGF, nesvacumab focuses on the Angiopoietin/Tie2 signaling pathway, a critical regulator of vascular remodeling and stability.

In the clinical landscape of March 2026, nesvacumab is recognized as a “vessel-destabilizing” agent. In a healthy body, Ang-2 and its partner Ang-1 work together to maintain blood vessel health. However, in the “hostile” environment of a tumor, Ang-2 levels are abnormally high, leading to the formation of “leaky,” disorganized, and dysfunctional blood vessels. Nesvacumab aims to block these signals, potentially normalizing the tumor’s blood supply to improve drug delivery or causing the vessels to collapse altogether.

• Generic Name: Nesvacumab.
• Code Name: REGN910.
• Drug Class: Monoclonal Antibody; Angiopoietin-2 (Ang-2) Inhibitor; Anti-angiogenic Agent.
• Mechanism: Selective binding to Ang-2, preventing its interaction with the Tie2 receptor on endothelial cells.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. As of March 2026, nesvacumab is not FDA-approved. It has been evaluated in Phase 1 and Phase 2 trials, both as a single agent and in combination with other anti-angiogenic drugs like aflibercept (Zaltrap).

What Is It and How Does It Work? (Mechanism of Action)

Nesvacumab works by interfering with the “reinforcement” system of tumor blood vessels.

1. The Angiopoietin/Tie2 Pathway

The Tie2 receptor is found on endothelial cells (the cells that line blood vessels). It has two main “keys” that fit into it:

• Angiopoietin-1 (Ang-1): The “stabilizer.” When Ang-1 binds to Tie2, it keeps vessels healthy and leak-proof.
• Angiopoietin-2 (Ang-2): The “destabilizer.” In the presence of high levels of Ang-2 (as seen in tumors), the stabilizing effect of Ang-1 is blocked.

2. Tumor Vessel Malformation

In a tumor, the high concentration of Ang-2 causes the vessels to become “plastic” and unstable.

• Increased Permeability: Vessels become “leaky,” which increases the pressure inside the tumor and makes it harder for chemotherapy to reach the cancer cells.
• Neovascularization: The instability makes it easier for new, disorganized vessels to sprout, fueling the tumor’s growth.

3. Therapeutic Blockade

Nesvacumab is an antibody that acts as a “sponge” for Ang-2.

1. Binding: It binds to circulating Ang-2 with high affinity.
2. Tie2 Restoration: By removing the excess Ang-2, the drug allows the stabilizing Ang-1 to once again bind to the Tie2 receptor.
3. Vascular Normalization: This can “prune” away the weakest tumor vessels and “normalize” others, potentially reducing tumor pressure and improving the delivery of other cancer-killing drugs.

FDA-Approved Clinical Indications

There are currently no FDA-approved oncology indications for nesvacumab.

Clinical research through 2026 has primarily focused on:

• Advanced Solid Tumors: Initial Phase 1 trials established safety and identified the optimal dose in patients with various metastatic cancers.
• Metastatic Colorectal Cancer (mCRC): Evaluated in combination with aflibercept and FOLFIRI chemotherapy.
• Hepatocellular Carcinoma (Liver Cancer): Studied as a way to disrupt the highly vascular nature of liver tumors.
• Ophthalmology (Related Drug): Interestingly, the technology behind nesvacumab led to the development of faricimab (Vabysmo), which is FDA-approved to treat wet AMD and DME by targeting both Ang-2 and VEGF.

Dosage and Administration Protocols

As an investigational drug, nesvacumab dosing is strictly managed within clinical trials (such as the REGN910 series).

Clinical Efficacy and Research Results

As of early 2026, the clinical journey of nesvacumab has provided valuable insights into the “dual-angiogenesis” approach.

• Synergy with Aflibercept: Phase 1b trials showed that combining nesvacumab with aflibercept (which targets VEGF) was safe and resulted in some durable stable disease in patients who had already failed multiple lines of treatment.
• Biomarker Response: Clinical data confirmed that the drug effectively lowered levels of circulating Ang-2 in the blood, proving it was successfully hitting its biological target.
• Vascular Normalization: Imaging studies (like dynamic contrast-enhanced MRI) in 2024–2025 provided evidence that nesvacumab could reduce the “leakiness” of tumor vessels, potentially creating a “window of opportunity” for chemotherapy to work better.

Safety Profile and Side Effects

The safety profile of nesvacumab is distinct from traditional chemotherapy and other anti-angiogenic agents.

Common Side Effects (>15%):

• Fatigue: The most frequently reported systemic symptom.
• Peripheral Edema: Swelling of the hands, ankles, or feet.
• Nausea and Diarrhea: Generally mild to moderate.
• Headache: Often reported during or shortly after the infusion.

Serious Risks:

• Hypertension: High blood pressure, a common “class effect” of drugs that target blood vessels.
• Proteinuria: Excess protein in the urine, which requires regular monitoring of kidney function.
• Thromboembolic Events: A potential risk of blood clots in the legs (DVT) or lungs (PE).
• Infusion Reactions: Rare reports of fever, chills, or low blood pressure during the IV drip.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, nesvacumab is being used to study “Vascular Niche Maintenance.” Researchers are investigating how the Ang-2/Tie2 pathway regulates the health of Hematopoietic Stem Cells in the bone marrow. In 2026, there is also intense focus on “Immune-Vascular Crosstalk.” Scientists are exploring if normalizing tumor vessels with nesvacumab can make it easier for CAR-T cells or checkpoint inhibitors to penetrate deep into a tumor. Furthermore, studies are exploring if nesvacumab can be used as a “preventative” therapy to stop microscopic metastases from forming their own blood supply.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Baseline Blood Pressure: Establishment of a baseline blood pressure and potential initiation of anti-hypertensive meds if needed.
• Urinalysis: To check for pre-existing proteinuria.
• Imaging: Baseline CT or MRI to measure tumor size before treatment.

“Do’s and Don’ts” List:

• DO report any new or worsening swelling in your legs or shortness of breath immediately, as these could be signs of a blood clot or heart stress.
• DO keep your bi-weekly infusion appointments, as the drug’s effect on tumor vessels requires consistent dosing.
• DON’T ignore sudden spikes in blood pressure; your oncology team can usually manage this with standard medication without stopping the nesvacumab.
• DON’T undergo major surgery while receiving nesvacumab without consulting your oncologist, as anti-angiogenic drugs can interfere with wound healing.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Nesvacumab (REGN910) is an investigational agent and is not approved by the U.S. FDA for any indication. Access is limited exclusively to registered clinical trials. Always consult with a qualified oncologist regarding your specific diagnosis and eligibility for research participation.